Zevra Therapeutics, Inc. (ZVRA)

NASDAQ: ZVRA · IEX Real-Time Price · USD
6.63
-0.17 (-2.50%)
At close: Feb 23, 2024, 4:00 PM
6.50
-0.13 (-1.96%)
After-hours: Feb 23, 2024, 6:39 PM EST
-2.50%
Market Cap 275.05M
Revenue (ttm) 16.56M
Net Income (ttm) -39.92M
Shares Out 41.49M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 174,915
Open 6.80
Previous Close 6.80
Day's Range 6.60 - 6.88
52-Week Range 3.89 - 7.28
Beta 1.78
Analysts Strong Buy
Price Target 18.00 (+171.49%)
Earnings Date Mar 5, 2024

About ZVRA

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use di... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2015
Employees 32
Stock Exchange NASDAQ
Ticker Symbol ZVRA
Full Company Profile

Financial Performance

In 2022, ZVRA's revenue was $10.46 million, a decrease of -63.50% compared to the previous year's $28.65 million. Losses were -$41.54 million, -33.95% less than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 171.49% from the latest price.

Price Target
$18.0
(171.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the ...

19 days ago - GlobeNewsWire

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shi...

4 weeks ago - GlobeNewsWire

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Arimoclomol NDA has been assigned a PDUFA action date of June 21, 2024 CELEBRATION, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.  (NasdaqGS: ZVRA) (Zevra or the Company), a rare di...

6 weeks ago - GlobeNewsWire

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Qu...

7 weeks ago - GlobeNewsWire

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for ar...

2 months ago - GlobeNewsWire

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

Acquisition includes OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra into commercial stage, diversifying its revenue and providing scale Settlement of Acer's w...

3 months ago - GlobeNewsWire

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra's revenue with FDA-approved OLPRUVA ® ...

3 months ago - GlobeNewsWire

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conferen...

4 months ago - GlobeNewsWire

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global Niemann-Pick ...

4 months ago - GlobeNewsWire

ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutic...

4 months ago - Business Wire

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

Christal Mickle transitions back to Chief Development Officer CELEBRATION, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease the...

4 months ago - GlobeNewsWire

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs

5 months ago - GlobeNewsWire

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Data generated to date indicate SDX is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future Phase 3 trial

5 months ago - GlobeNewsWire

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management ...

5 months ago - GlobeNewsWire

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation feat...

6 months ago - GlobeNewsWire

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

CELEBRATION, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management ...

6 months ago - GlobeNewsWire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure

6 months ago - GlobeNewsWire

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023

6 months ago - GlobeNewsWire

Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science, data, and patient need to create transforma...

7 months ago - GlobeNewsWire

Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that...

7 months ago - GlobeNewsWire

Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

CELEBRATION, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced th...

7 months ago - GlobeNewsWire

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

CELEBRATION, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, announced its expe...

8 months ago - GlobeNewsWire

Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced ex...

9 months ago - GlobeNewsWire

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Co...

9 months ago - GlobeNewsWire

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

Christal Mickle, Co-Founder and Chief Development Officer, appointed to serve as interim President and CEO effective June 1, 2023

10 months ago - GlobeNewsWire